| Name | Title | Contact Details |
|---|
Sensei is an evidenced-based company that develops technology and offers healthier living programs and services to help people find greater wellbeing. Its first retreat is located at the Sensei Lānaʻi, A Four Seasons Resort on Larry Ellison`s secluded Hawaiian island of Lānaʻi, is where people come to learn the Sensei Way philosophy in the most luxurious and inspiring settings. Each guest`s stay is highly customized to help align their actions with their intentions by offering private wellness consultations, small indoor and outdoor classes, relaxing treatments in individual spa hales, outdoor adventures and innovative dining guided by the Sensei nutritional philosophy.
Veltek Associates, Inc. is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Las Vegas, Nevada, GPO Plus, Inc. (OTC: $GPOX) is a publicly traded global holding company of industry-specific Group Purchasing Organizations (GPO). The main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry, and cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry.
Headquartered in Memphis, Tennessee, Accredo Health Group, Inc., provides specialty pharmacy and related services for patients with certain complex and chronic conditions through our unique Therapeutic Resource Centers. Accredo is a wholly owned subsidiary of Express Scripts. Accredo’s Therapeutic Resource Centers are segmented by therapy and provide targeted therapy management programs for the following therapeutic areas: Rheumatoid arthritis Multiple sclerosis Oncology Hepatitis C Immune disorders Pulmonary arterial hypertension Hemophilia Other specialty therapies with dedicated care teams (RSV, growth deficiencies, etc.) Our services cover the range of needs posed by specialty pharmacy care. Our pharmacists and other healthcare professionals talk frequently with patients over the phone, helping them follow their treatment and educating them about their condition. And our reimbursement specialists provide b enefits research services, with an explanation to the patient or patient’s caregiver of any financial responsibility he/she may have plus prior authorization determination.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.